Ciba Geigy

What Ciba Geigy does

Ciba Geigy Drugs Private Limited is an Indian unlisted pharmaceutical manufacturer incorporated in 2008 and headquartered in Delhi, India, with a production facility in Haridwar and a regional office in the Mumbai metropolitan area. The company manufactures a broad portfolio of generic formulations and DCGI (Drugs Controller General of India) approved molecules across multiple dosage forms — tablets, capsules, dry syrups, liquid syrups, injections, creams, gels, and sanitizers — covering therapeutic categories such as anti-infectives, cardiovascular, respiratory, gastrointestinal, dermatological, and nutritional supplements. Reported production scale includes 540+ non-beta lactum tablet SKUs, 47 non-beta lactum capsule SKUs, and 120+ beta lactum products. Trademarked brands in the catalog include ADELPHANE ESIDREX, LEDERMYCIN, RIFATER, CEFIZOX, GARAMYCIN, PROFASI, ISOGEL, COSAVIL, SUKCEE/SUKEE, and CIBA-CLEAN sanitizers.

The business model is straightforward generic-pharma manufacturing and distribution: the company produces formulations in its own facility and sells into both domestic Indian and international markets (the company claims a worldwide footprint targeting "developed and developing markets"). Revenue mechanics are not publicly disclosed; the revenue stream is recorded as "pharmaceutical products sales" from generic formulations and DCGI-approved molecules. Pricing is not disclosed publicly, and no licensing, royalty, subscription, or platform revenue lines are identified. The company is founder-led by Mr. Labhu Ram Garg as Founding Chairperson, with a headcount of 11–50 employees — a profile consistent with a small, privately held domestic generics manufacturer rather than a scaled export-oriented player. No institutional investors, parent company, subsidiaries, partnerships, or alliances were identified in the source material, and the firm's digital footprint (a basic WordPress site with blog posts dated January 2022 and minimal product detail) suggests limited marketing or e-commerce infrastructure.

Name

Ciba Geigy

Legal name

Ciba Geigy Drugs Private Limited

Website

https://cibageigydrugs.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Ciba Geigy Drugs Private Limited is an India-based, privately held generic pharmaceutical manufacturer founded in 2008, producing DCGI-approved formulations across tablets, capsules, syrups, injections, and sanitizers for domestic and international markets.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industry

Hand Sanitizers & Antibacterial Personal Care (CRADANAI)

Keywords

• Generic pharmaceutical manufacturing
• DCGI approved formulations
• Pharmaceutical tablets capsules
• Antibiotic formulations
• Vitamin supplement tablets

Headquarters

HQ city

Saint Gabriel

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Pharmaceutical products sales: Revenue generated from manufacturing and selling quality generic formulations and DCGI approved molecules for domestic and international markets.

Core offering

Ciba Geigy Drugs Private Limited is an innovation-led pharmaceutical company that manufactures and sells a wide range of affordable generic formulations and DCGI-approved molecules across multiple dosage forms including tablets, capsules, syrups, dry syrups, injections, creams, and gels. The company produces over 540 Non-Beta Lactum tablets, 47 Non-Beta Lactum capsules, and 120+ Beta Lactum products, serving both domestic Indian and international pharmaceutical markets. Its portfolio spans therapeutic categories including anti-infectives, cardiovascular, respiratory, dermatological, gastrointestinal, and nutritional supplements.

Product overview

Ciba Geigy is an innovation-led pharmaceutical company producing a wide range of affordable, quality generic formulations and DCGI-approved molecules. The product portfolio includes trade mark products (ADELPHANE ESIDREX, LEDERMYCIN, RIFATER, CEBEXIN, CEFIZOX, GARAMYCIN, ISOGEL), over-the-counter products (COSAVIL, SUKCEE, FENCYDRYL), antibiotics (AUG CLAVE, CEFIX-O, MOXCI), vitamin supplements (SUKEE, CHEW-C, EVCIB D3), sanitizers (CIBA-CLEAN, GANGAJAL, GRATTUS), and extensive lists of approved generic drugs across multiple formulations including tablets, capsules, syrups, suspensions, injections, creams, and gels. The company operates across therapeutic categories including anti-infectives, cardiovascular, respiratory, dermatological, gastrointestinal, and nutritional supplements.

Differentiator

Problem solved

Functional benefit

Products and services

• ADELPHANE ESIDREX TABLETS
• CORBUTYL TABLETS
• LEDERMYCIN TABLETS
• RIFATER TABLETS
• CEBEXIN CAPSULES
• IDICIN CAPSULES
• WALAGESIC CAPSULES

Segments2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Expansion highlights4 records

Broad incumbents

• Sun Pharmaceutical Industries: India's largest specialty generic pharmaceutical company, manufacturing formulations across chronic and acute therapeutic categories with strong US generics presence. Same fundamental business model (Indian generic formulations manufacturing) and therapeutic coverage as Ciba Geigy, with established DCGI and global regulatory track record.
• Glenmark Pharmaceuticals: Indian pharmaceutical company with formulations across dermatology, respiratory, and cardiovascular, with growing presence in specialty and biosimilars. Operates globally from Indian manufacturing base with comparable regulatory approach to Ciba Geigy.
• Lupin Limited: Major Indian generic pharmaceutical manufacturer with global presence across formulations, APIs, and biosimilars. Directly comparable in product categories (cardiovascular, anti-infectives, dermatology) and in targeting both developed and emerging markets from Indian manufacturing base.
• Cipla Limited: One of India's largest generic pharmaceutical manufacturers, with a portfolio spanning respiratory, cardiovascular, anti-infectives, and OTC categories across global markets. Highly comparable business model and product breadth to Ciba Geigy, but at vastly greater scale and with extensive international regulatory approvals.
• Torrent Pharmaceuticals: Indian pharmaceutical company with focus on generics, particularly in cardiovascular, CNS, and gastrointestinal segments with growing international presence. Comparable therapeutic category focus and Indian-based manufacturing footprint serving developed and emerging markets.
• Aurobindo Pharma: Large Indian generics manufacturer with extensive formulation portfolio across antibiotics, anti-retrovirals, CNS, and cardiovascular categories. Operates DCGI-approved Indian facilities serving global markets in a manner structurally analogous to Ciba Geigy, though at vastly greater scale.
• Alkem Laboratories: India-based pharmaceutical manufacturer producing generics across anti-infectives, vitamins, and chronic disease categories. Similar mid-sized Indian pharma profile with strong domestic and growing international presence in formulations.

Direct peers

• Marksans Pharma: Mid-sized Indian pharmaceutical manufacturer specializing in generic formulations across dosage forms (tablets, capsules, liquids) with strong API capability. Comparable business structure of an Indian manufacturer of generic formulations targeting regulated and semi-regulated global markets.
• Mankind Pharma: Mid-sized Indian pharmaceutical company with a strong portfolio of generics, OTC, vitamins, and consumer health products including sanitizers. Most directly comparable peer in terms of broad generic-plus-OTC portfolio, Indian manufacturing focus, and venture into consumer health adjacencies like sanitizers and supplements.
• Jenburkt Pharmaceuticals: Small-to-mid Indian generic pharmaceutical company focused on niche formulations across multiple therapeutic categories. Closer peer in scale than large incumbents, with comparable portfolio of branded generic formulations for Indian and select export markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ciba-geigy-corp

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ciba Geigy